Nektar Therapeutics (XTER:ITH0) 6-Month Share Buyback Ratio: -67.48% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:ITH0 Nektar Therapeutics XTER:ITH0
35 GF Score
Price €64.28
GF Value €4.99
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Nektar Therapeutics 6-Month Share Buyback Ratio?

Nektar Therapeutics XTER:ITH0 +2.13% 35 6-Month Share Buyback Ratio is -67.48 as of Jun. 2026. GuruFocus rates XTER:ITH0 with a GF Score™ of 35/100 and a GF Value™ of €4.99 (Significantly Overvalued). The stock has 4 warning signs investors should review.

6-Month Share Buyback Ratio does not apply to companies whose reporting frequency is 12 months.

XTER:ITH0
35GF Score
Nektar Therapeutics XTER:ITH0
6-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 6-Month Share Buyback Ratio of -67.48 mean?
Nektar Therapeutics (XTER:ITH0) has a 6-Month Share Buyback Ratio of -67.48 as of Jun. 2026. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' 6-Month Share Buyback Ratio too high?
Nektar Therapeutics' current 6-Month Share Buyback Ratio is -67.48. Overall, Nektar Therapeutics has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' 6-Month Share Buyback Ratio compare to ?
Nektar Therapeutics' 6-Month Share Buyback Ratio of -67.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Share Buyback Ratio for a Biotechnology company?
A good 6-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 6-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Share Buyback Ratio mean?
A high 6-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Nektar Therapeutics and its competitors. Nektar Therapeutics's current 6-Month Share Buyback Ratio is -67.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (XTER:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.99, compared to a current price of €64.28 — trading 1188.2% above its estimated fair value. The current 6-Month Share Buyback Ratio is -67.48. Nektar Therapeutics' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Share Buyback Ratio calculated?
6-Month Share Buyback Ratio is calculated from a company's financial statements. For Nektar Therapeutics (XTER:ITH0), the current 6-Month Share Buyback Ratio is -67.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (XTER:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €64.28 is trading 1188.2% above its estimated GF Value™ of €4.99. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for XTER:ITH0:

  • 6-Month Share Buyback Ratio: -67.48
  • GF Value™: €4.99 vs. price of €64.28 (1188.2% above fair value)
  • GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the XTER:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Comparable Companies
Other Exchanges NKTR:USA0UNL:UK
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
35GF Score

Get the complete analysis for XTER:ITH0

6-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.28
Price
€4.99
GF Value